Skip to content
Loop Biz – Lifestyle
Author:
InflaRx N.V.
InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos
June 30, 2026
InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares
May 8, 2026
InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares
May 6, 2026
InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases
May 6, 2026
InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes
May 4, 2026
InflaRx to Report First Quarter 2026 Results on May 7, 2026
May 1, 2026
InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
April 28, 2026
InflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR Inhibitor
April 9, 2026
InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium
March 31, 2026
InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual Meeting
March 30, 2026
1
2
Next Page
→